PAHC
Phibro Animal Health Corporation
PAHC's fundamentals are strong and it looks cheap: trading at 14x earnings, below its usual 21x. Analysts expect strong earnings growth.
PAHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Under pressure | |
| Stable |
PAHC's profitability is currently strong, and its revenue and balance sheet are stable, but its cash flow is under pressure.
PAHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.8x | $35.46 | — |
| Cheap | 14x | $35.90 | +1.2% |
| Current | 14x | $35.46 | — |
| Fair | 21x | $52.34 | +48% |
| Expensive | 37x | $93.48 | +164% |
Historical ranges are pointers, not guarantees.
PAHC's PE is in its cheap range at 14x. If earnings grow as analysts expect, today's price would be 9.8x next year's earnings.
PAHC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for PAHC, with profitability improving.
PAHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.61 | +44% |
| Q3 2026 | $2.50 | +50% |
| Q2 2026 | $2.43 | +104% |
| Q1 2026 | $2.34 | +200% |
| Q4 2025 | $2.26 | +371% |
| Q3 2025 | $1.67 | +288% |
| Q2 2025 | $1.19 | +1883% |
| Q1 2025 | $0.78 | +144% |
| Q4 2024 | $0.48 | +33% |
PAHC's earnings per share have climbed steadily: $2.50 over the past year, up 50% from the year before, and higher year over year for eight quarters in a row.
PAHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $386.8M | +6.3% |
| Q2 2026 | $396.7M | +4.8% |
| Q1 2026 | $383.5M | +10% |
| Q4 2025 | $373.9M | +21% |
| Q3 2025 | $363.9M | +40% |
| Q2 2025 | $378.7M | +39% |
| Q1 2025 | $347.8M | +32% |
| Q4 2024 | $309.3M | +24% |
PAHC's revenue has grown year over year for 12 quarters in a row: $387M last quarter, up 6.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -1.3 points |
| Q2 2026 | 12% | +3.2 points |
| Q1 2026 | 12% | +2 points |
| Q4 2025 | 13% | +5.2 points |
| Q3 2025 | 14% | +7.3 points |
| Q2 2025 | 8.9% | +2.2 points |
| Q1 2025 | 9.6% | +2.1 points |
| Q4 2024 | 8.3% | +2 points |
PAHC's operating margin was 13% last quarter, down 1.3 points from the same quarter a year ago.
PAHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $7.3M | +$11.8M |
| Q2 2026 | $5.2M | -36% |
| Q1 2026 | $890K | -97% |
| Q4 2025 | $8.3M | +$13M |
| Q3 2025 | -$4.5M | -248% |
| Q2 2025 | $8.1M | -47% |
| Q1 2025 | $35.4M | +2011% |
| Q4 2024 | -$4.7M | -123% |
PAHC still generates free cash flow, though less than at its 2025 peak: $22M over the past year.
PAHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -7K shares |
| 1 year | +0.2% | +80K shares |
| 3 years | +1.1% | +453K shares |
| 5 years | +1.1% | +453K shares |
| Available history | +1.1% | +453K shares |
PAHC has 41M diluted shares, about the same as a year ago.
PAHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.2x | Moderate |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.9x | Moderate |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 4.2x | High |
| Q4 2024 | 4.8x | High |
PAHC's net debt is about 2.2 years of its operating earnings (EBITDA), down from 2.9 years a year ago.
PAHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.1 | Neutral |
| Stochastic | 36.1 | Neutral |
PAHC's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
PAHC PE vs Healthcare Sector
| Metric | PAHC | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 45% below |
| PE % | 15 | 29 | 14 pts below |
PAHC is trading at 14x earnings, a 45% discount to the Healthcare sector's median of 26x.
PAHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.9 | 3.8% below |
| 20 week MA | $35.8 | 0.8% below |
| 50 week MA | $40.6 | 13% below |
| 100 week MA | $34.4 | 3% above |
| 200 week MA | $25.0 | 42% above |
PAHC has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 42% above its 200-week average.
PAHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.8 | $19.1 | -23% |
| 2021 | $19.1 | $20.7 | +8.3% |
| 2022 | $20.7 | $13.9 | -33% |
| 2023 | $13.9 | $11.6 | -17% |
| 2024 | $11.6 | $21.1 | +82% |
| 2025 | $21.1 | $38.2 | +81% |
| 2026 YTD | $38.2 | $35.5 | -7.1% |
PAHC has finished lower in three of the last six years. It's down 7.1% so far in 2026.